

Amyris Advances to Regulatory Stage with Another Significant Health & Nutrition Molecule

EMERYVILLE, Calif., Nov. 18, 2019 /PRNewswire/ -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it is moving into the regulatory stage with a new, undisclosed health and nutrition molecule. Amyris has proven its capability to produce health and nutrition molecules at commercial scale with three others; artemisinin, vitamin E and, most recently, Reb M. Amyris developed a process for this ingredient that enables the highest purity at the lowest cost and has now successfully manufactured material via large scale fermentation. The company plans to submit formal regulatory filings for this ingredient (currently not being named due to partner's requirements) where required for rapid approval and market entry during the first half of 2020.

"Our ability to speed time to market at lower cost and with better purity is why the leading companies continue to rely on Amyris," said John Melo, Amyris President and CEO. "This molecule serving a large market in the health and nutrition space, is another example of our development success and we are pleased to be readying it for regulatory approval. We are pleased with our continued delivery momentum in the fourth quarter and the potential of 2020 delivering a record year for new product launches and for the health and nutrition business becoming our largest revenue activity. We are very excited about the continued potential of synthetic biology to deliver a significant impact in making the world healthier one molecule at a time and our transition to profitable growth."

About Amyris

Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products and services across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as the expected submission of formal regulatory filings for a new health and nutrition ingredient and related approval and market entry for such ingredient, including the timing thereof, anticipated new product launches in 2020, expected revenue from Amyris's health and nutrition business, and anticipated business growth, including the profitability thereof. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund operating and capital expenses, risks related to potential delays or failures in development, production and commercialization of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo and No Compromise are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.

SOURCE Amyris, Inc.

For further information: Peter DeNardo, Director, Investor Relations and Corporate Communications, Amyris, Inc., +1 (510) 740-7481, investor@amyris.com

<https://investors.amyris.com/2019-11-18-Amyris-Advances-to-Regulatory-Stage-with-Another-Significant-Health-Nutrition-Molecule>